메뉴 건너뛰기




Volumn 7, Issue 9, 2009, Pages 1053-1062

Entecavir for the long-term treatment of chronic hepatitis B

Author keywords

Cirrhosis; Entecavir; Hepatitis B; Hepatocellular carcinoma; Liver; Nucleoside analogue; Resistance

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; VIRUS DNA;

EID: 73949102363     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.09.75     Document Type: Review
Times cited : (8)

References (57)
  • 1
    • 4644354309 scopus 로고    scopus 로고
    • Hepatitis B vaccines: WHO position paper
    • World Health Organization
    • World Health Organization. Hepatitis B vaccines: WHO position paper. Wkly Epidemiol. Rec. 79, 255-263 (2004).
    • (2004) Wkly Epidemiol. Rec , vol.79 , pp. 255-263
  • 2
    • 58749111990 scopus 로고    scopus 로고
    • Sorrell MF, Belongia EA, Costa J et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann. Intern. Med. 150 (2), 104-110 (2009).
    • Sorrell MF, Belongia EA, Costa J et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann. Intern. Med. 150 (2), 104-110 (2009).
  • 3
    • 33646413672 scopus 로고    scopus 로고
    • The global health burden of infection-associated cancers in the year 2002
    • Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118 (12), 3030-3044 (2006).
    • (2006) Int. J. Cancer , vol.118 , Issue.12 , pp. 3030-3044
    • Parkin, D.M.1
  • 4
    • 1642410856 scopus 로고    scopus 로고
    • Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures
    • Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 11 (2), 97-107 (2004).
    • (2004) J. Viral Hepat , vol.11 , Issue.2 , pp. 97-107
    • Lavanchy, D.1
  • 5
    • 33644858331 scopus 로고    scopus 로고
    • Predicting cirrhosis risk based on the level of circulating hepatitis B viral load
    • Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130 (3), 678-686 (2006).
    • (2006) Gastroenterology , vol.130 , Issue.3 , pp. 678-686
    • Iloeje, U.H.1    Yang, H.I.2    Su, J.3    Jen, C.L.4    You, S.L.5    Chen, C.J.6
  • 6
    • 33746675024 scopus 로고    scopus 로고
    • Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study
    • Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am. J. Gastroenterol. 101 (8), 1797-1803 (2006).
    • (2006) Am. J. Gastroenterol , vol.101 , Issue.8 , pp. 1797-1803
    • Chen, G.1    Lin, W.2    Shen, F.3    Iloeje, U.H.4    London, W.T.5    Evans, A.A.6
  • 7
    • 29944436855 scopus 로고    scopus 로고
    • Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (1), 65-73 (2006). •• Prospective cohort study of untreated HBV-infected individuals with over 11 years of follow-up that described a linear relationship between increasing serum HBV DNA and the development of hepatocellular carcinoma (HCC), demonstrating that the degree of viremia predicts HCC risk, independent of cirrhosis, hepatitis B e antigen (HBeAg) seropositivity, or alanine aminotransferase levels.
    • Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (1), 65-73 (2006). •• Prospective cohort study of untreated HBV-infected individuals with over 11 years of follow-up that described a linear relationship between increasing serum HBV DNA and the development of hepatocellular carcinoma (HCC), demonstrating that the degree of viremia predicts HCC risk, independent of cirrhosis, hepatitis B e antigen (HBeAg) seropositivity, or alanine aminotransferase levels.
  • 8
    • 51049117284 scopus 로고    scopus 로고
    • Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma
    • Yang HI, Yeh SH, Chen PJ et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J. Natl Cancer Inst. 100 (16), 1134-1143 (2008).
    • (2008) J. Natl Cancer Inst , vol.100 , Issue.16 , pp. 1134-1143
    • Yang, H.I.1    Yeh, S.H.2    Chen, P.J.3
  • 9
    • 38349094747 scopus 로고    scopus 로고
    • High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma
    • Chan HL, Tse CH, Mo F et al. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J. Clin. Oncol. 26 (2), 177-182 (2008).
    • (2008) J. Clin. Oncol , vol.26 , Issue.2 , pp. 177-182
    • Chan, H.L.1    Tse, C.H.2    Mo, F.3
  • 10
    • 19544391413 scopus 로고    scopus 로고
    • Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351 (15), 1521-1531 (2004). •• Prospective multicenter, randomized, double-blind, placebo-controlled trial in which patients with advanced fibrosis who were randomized to receive antiviral therapy with lamivudine had a lower incidence of HCC or disease progression within 3 years of follow-up.
    • Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351 (15), 1521-1531 (2004). •• Prospective multicenter, randomized, double-blind, placebo-controlled trial in which patients with advanced fibrosis who were randomized to receive antiviral therapy with lamivudine had a lower incidence of HCC or disease progression within 3 years of follow-up.
  • 11
    • 33847701354 scopus 로고    scopus 로고
    • Chronic hepatitis B
    • Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 45 (2), 507-539 (2007).
    • (2007) Hepatology , vol.45 , Issue.2 , pp. 507-539
    • Lok, A.S.1    McMahon, B.J.2
  • 12
    • 57149091722 scopus 로고    scopus 로고
    • Keeffe EB, Dieterich DT, Han SH et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin. Gastroenterol. Hepatol. 6 (12), 1315-1341 (2008). • Comprehensive treatment algorithm developed by an international expert panel outlining treatment strategies for chronic hepatitis B based on current evidence, including selection of treatment candidates and recommended antiviral agents, on-treatment monitoring and management of antiviral resistance.
    • Keeffe EB, Dieterich DT, Han SH et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin. Gastroenterol. Hepatol. 6 (12), 1315-1341 (2008). • Comprehensive treatment algorithm developed by an international expert panel outlining treatment strategies for chronic hepatitis B based on current evidence, including selection of treatment candidates and recommended antiviral agents, on-treatment monitoring and management of antiviral resistance.
  • 13
    • 58149296156 scopus 로고    scopus 로고
    • EASL Clinical Practice Guidelines: Management of chronic hepatitis B
    • European Association for the Study of the Liver
    • European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J. Hepatol. 50 (2), 227-242 (2009).
    • (2009) J. Hepatol , vol.50 , Issue.2 , pp. 227-242
  • 14
    • 33644506166 scopus 로고    scopus 로고
    • Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005
    • Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 43 (2 Suppl. 1), S173-S181 (2006).
    • (2006) Hepatology , vol.43 , Issue.2 SUPPL. 1
    • Yim, H.J.1    Lok, A.S.2
  • 15
    • 27444441182 scopus 로고    scopus 로고
    • Prognostic determinants for chronic hepatitis B in Asians: Therapeutic implications
    • Yuen MF, Yuan HJ, Wong DK et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 54 (11), 1610-1614 (2005).
    • (2005) Gut , vol.54 , Issue.11 , pp. 1610-1614
    • Yuen, M.F.1    Yuan, H.J.2    Wong, D.K.3
  • 16
    • 34247222010 scopus 로고    scopus 로고
    • Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B
    • Ghany M, Liang TJ. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 132 (4), 1574-1585 (2007).
    • (2007) Gastroenterology , vol.132 , Issue.4 , pp. 1574-1585
    • Ghany, M.1    Liang, T.J.2
  • 17
    • 4644298430 scopus 로고    scopus 로고
    • Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B
    • Fung SK, Wong F, Hussain M, Lok AS. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J. Viral Hepat. 11 (5), 432-438 (2004).
    • (2004) J. Viral Hepat , vol.11 , Issue.5 , pp. 432-438
    • Fung, S.K.1    Wong, F.2    Hussain, M.3    Lok, A.S.4
  • 18
    • 58149316191 scopus 로고    scopus 로고
    • Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy
    • Shouval D, Lai CL, Chang TT et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy J. Hepatol. 50 (2), 289-295 (2009).
    • (2009) J. Hepatol , vol.50 , Issue.2 , pp. 289-295
    • Shouval, D.1    Lai, C.L.2    Chang, T.T.3
  • 19
    • 54849146600 scopus 로고    scopus 로고
    • Hepatitis B virus infection
    • Dienstag JL. Hepatitis B virus infection. N. Engl. J. Med. 359 (14), 1486-1500 (2008).
    • (2008) N. Engl. J. Med , vol.359 , Issue.14 , pp. 1486-1500
    • Dienstag, J.L.1
  • 20
    • 73949132784 scopus 로고    scopus 로고
    • entecavir, Bristol-Meyers Squibb Company, Princeton, NJ, USA, January
    • Baraclude® (entecavir). Bristol-Meyers Squibb Company, Princeton, NJ, USA. Product information, revised January 2009.
    • (2009) Product information, revised
    • Baraclude®1
  • 22
    • 0032907705 scopus 로고    scopus 로고
    • Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus
    • Yamanaka G, Wilson T, Innaimo S et al. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob. Agents Chemother. 43 (1), 190-193 (1999).
    • (1999) Antimicrob. Agents Chemother , vol.43 , Issue.1 , pp. 190-193
    • Yamanaka, G.1    Wilson, T.2    Innaimo, S.3
  • 23
    • 0031761652 scopus 로고    scopus 로고
    • In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir
    • Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob. Agents Chemother. 42 (12), 3200-3208 (1998).
    • (1998) Antimicrob. Agents Chemother , vol.42 , Issue.12 , pp. 3200-3208
    • Seifer, M.1    Hamatake, R.K.2    Colonno, R.J.3    Standring, D.N.4
  • 24
    • 34247107229 scopus 로고    scopus 로고
    • Inhibition of hepatitis B virus polymerase by entecavir
    • Langley DR, Walsh AW, Baldick CJ et al. Inhibition of hepatitis B virus polymerase by entecavir. J. Virol. 81 (8), 3992-4001 (2007).
    • (2007) J. Virol , vol.81 , Issue.8 , pp. 3992-4001
    • Langley, D.R.1    Walsh, A.W.2    Baldick, C.J.3
  • 25
    • 0035114188 scopus 로고    scopus 로고
    • The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance
    • Ono SK, Kato N, Shiratori Y et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J. Clin. Invest. 107 (4), 449-455 (2001).
    • (2001) J. Clin. Invest , vol.107 , Issue.4 , pp. 449-455
    • Ono, S.K.1    Kato, N.2    Shiratori, Y.3
  • 26
    • 0035991863 scopus 로고    scopus 로고
    • Efficacies of entecavir against lamivudineresistant hepatitis B virus replication and recombinant polymerases in vitro
    • Levine S, Hernandez D, Yamanaka G et al. Efficacies of entecavir against lamivudineresistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob. Agents Chemother. 46 (8), 2525-2532 (2002).
    • (2002) Antimicrob. Agents Chemother , vol.46 , Issue.8 , pp. 2525-2532
    • Levine, S.1    Hernandez, D.2    Yamanaka, G.3
  • 27
    • 26844500312 scopus 로고    scopus 로고
    • A dose-ranging study of the effcacy and tolerability of entecavir in lamivudinerefractory chronic hepatitis B patients
    • Chang TT, Gish RG, Hadziyannis SJ et al. A dose-ranging study of the effcacy and tolerability of entecavir in lamivudinerefractory chronic hepatitis B patients. Gastroenterology 129 (4), 1198-1209 (2005).
    • (2005) Gastroenterology , vol.129 , Issue.4 , pp. 1198-1209
    • Chang, T.T.1    Gish, R.G.2    Hadziyannis, S.J.3
  • 28
    • 0035991456 scopus 로고    scopus 로고
    • Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B
    • Wolters LM, Hansen BE, Niesters HG, DeHertogh D, de Man RA. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J. Hepatol. 37 (1), 137-144 (2002).
    • (2002) J. Hepatol , vol.37 , Issue.1 , pp. 137-144
    • Wolters, L.M.1    Hansen, B.E.2    Niesters, H.G.3    DeHertogh, D.4    de Man, R.A.5
  • 29
    • 58949087420 scopus 로고    scopus 로고
    • Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir
    • Leung N, Peng CY, Hann HW et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 49 (1), 72-79 (2009).
    • (2009) Hepatology , vol.49 , Issue.1 , pp. 72-79
    • Leung, N.1    Peng, C.Y.2    Hann, H.W.3
  • 30
    • 33644818518 scopus 로고    scopus 로고
    • A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
    • Prospective, randomized, double-blind clinical trial that demonstrated greater viral suppression, biochemical response and histologic improvement in HBeAgpositive patients who received entecavir in comparison with lamivudine, •
    • Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 354 (10), 1001-1010 (2006). • Prospective, randomized, double-blind clinical trial that demonstrated greater viral suppression, biochemical response and histologic improvement in HBeAgpositive patients who received entecavir in comparison with lamivudine.
    • (2006) N. Engl. J. Med , vol.354 , Issue.10 , pp. 1001-1010
    • Chang, T.T.1    Gish, R.G.2    de Man, R.3
  • 31
    • 35649020315 scopus 로고    scopus 로고
    • Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B
    • Gish RG, Lok AS, Chang TT et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 133 (5), 1437-1444 (2007).
    • (2007) Gastroenterology , vol.133 , Issue.5 , pp. 1437-1444
    • Gish, R.G.1    Lok, A.S.2    Chang, T.T.3
  • 32
    • 70350037583 scopus 로고    scopus 로고
    • Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naive HBeAg-positive patients with chronic hepatitis B
    • Epub ahead of print
    • Chang TT, Chao YC, Gorbakov VV et al. Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J. Viral Hepat. (2009) (Epub ahead of print).
    • (2009) J. Viral Hepat
    • Chang, T.T.1    Chao, Y.C.2    Gorbakov, V.V.3
  • 33
    • 73949091802 scopus 로고    scopus 로고
    • Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B
    • Epub ahead of print
    • Gish RG, Chang TT, Lai CL et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J. Viral Hepat. (2009) (Epub ahead of print).
    • (2009) J. Viral Hepat
    • Gish, R.G.1    Chang, T.T.2    Lai, C.L.3
  • 34
    • 58649118949 scopus 로고    scopus 로고
    • Five years of continuous entecavir for nucleoside-naive HBeAg+ chronic hepatitis B: Results from study ETV-901 [abstract]
    • Han SH, Chang TT, Chao YC et al. Five years of continuous entecavir for nucleoside-naive HBeAg+ chronic hepatitis B: results from study ETV-901 [abstract]. Hepatology 48 (S1), 705A-706A (2008).
    • (2008) Hepatology , vol.48 , Issue.S1
    • Han, S.H.1    Chang, T.T.2    Chao, Y.C.3
  • 35
    • 33644822860 scopus 로고    scopus 로고
    • Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B
    • Prospective, randomized, double-blind clinical trial that demonstrated greater viral suppression, biochemical response and histologic improvement in HBeAgnegative patients who received entecavir in comparison with lamivudine, •
    • Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 354 (10), 1011-1020 (2006). • Prospective, randomized, double-blind clinical trial that demonstrated greater viral suppression, biochemical response and histologic improvement in HBeAgnegative patients who received entecavir in comparison with lamivudine.
    • (2006) N. Engl. J. Med , vol.354 , Issue.10 , pp. 1011-1020
    • Lai, C.L.1    Shouval, D.2    Lok, A.S.3
  • 36
    • 33744531146 scopus 로고    scopus 로고
    • Entecavir for treatment of lamivudinerefractory, HBeAg-positive chronic hepatitis B
    • Sherman M, Yurdaydin C, Sollano J et al. Entecavir for treatment of lamivudinerefractory, HBeAg-positive chronic hepatitis B. Gastroenterology 130 (7), 2039-2049 (2006).
    • (2006) Gastroenterology , vol.130 , Issue.7 , pp. 2039-2049
    • Sherman, M.1    Yurdaydin, C.2    Sollano, J.3
  • 37
    • 47149108478 scopus 로고    scopus 로고
    • Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved virologic, biochemical, and serology outcomes through 96 weeks
    • Sherman M, Yurdaydin C, Simsek H et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 48 (1), 99-108 (2008).
    • (2008) Hepatology , vol.48 , Issue.1 , pp. 99-108
    • Sherman, M.1    Yurdaydin, C.2    Simsek, H.3
  • 38
    • 66149115173 scopus 로고    scopus 로고
    • Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy
    • Summary of long-term resistance development in patients treated with entecavir for chronic HBV infection based on comprehensive resistance monitoring of cohorts treated in prospective studies with at least 5 years of follow-up, •
    • Tenney DJ, Rose RE, Baldick CJ et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49 (5), 1503-1514 (2009). • Summary of long-term resistance development in patients treated with entecavir for chronic HBV infection based on comprehensive resistance monitoring of cohorts treated in prospective studies with at least 5 years of follow-up.
    • (2009) Hepatology , vol.49 , Issue.5 , pp. 1503-1514
    • Tenney, D.J.1    Rose, R.E.2    Baldick, C.J.3
  • 39
    • 70350133508 scopus 로고    scopus 로고
    • Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients [abstract]
    • S
    • Tenney DJ, Pokornowski KA, Rose RE et al. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients [abstract]. J. Hepatol. 50 (Suppl. 1), S10 (2009).
    • (2009) J. Hepatol , vol.50 , Issue.SUPPL. 1 , pp. 10
    • Tenney, D.J.1    Pokornowski, K.A.2    Rose, R.E.3
  • 40
    • 66149164719 scopus 로고    scopus 로고
    • Antiviral resistance and hepatitis B therapy
    • Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology 49 (Suppl. 5), S174-S184 (2009).
    • (2009) Hepatology , vol.49 , Issue.SUPPL. 5
    • Ghany, M.G.1    Doo, E.C.2
  • 41
    • 73949119385 scopus 로고    scopus 로고
    • Long-term histologic improvement with entecavir (ETV) therapy in patients with chronic hepatitis B (CHB) from Japanese and worldwide development programs [abstract]
    • Liaw YF, Chang TT, Wu SS et al. Long-term histologic improvement with entecavir (ETV) therapy in patients with chronic hepatitis B (CHB) from Japanese and worldwide development programs [abstract]. Gastroenterology 136 (5, Suppl. 1), A798-A799 (2009).
    • (2009) Gastroenterology , vol.136 , Issue.5 and SUPPL. 1
    • Liaw, Y.F.1    Chang, T.T.2    Wu, S.S.3
  • 42
    • 73949122888 scopus 로고    scopus 로고
    • Regression of fbrosis/cirrhosis with long-term entecavir therapy in chronic hepatitis B (CHB) patients with baseline bridging fibrosis or cirrhosis: Results from studies ETV-022,-027 and-901 [abstract]
    • Schiff ER, Lee SS, Chao YC et al. Regression of fbrosis/cirrhosis with long-term entecavir therapy in chronic hepatitis B (CHB) patients with baseline bridging fibrosis or cirrhosis: results from studies ETV-022,-027 and-901 [abstract]. Gastroenterology 136 (5 Suppl. 1), A866 (2009).
    • (2009) Gastroenterology , vol.136 , Issue.5 SUPPL. 1
    • Schiff, E.R.1    Lee, S.S.2    Chao, Y.C.3
  • 43
    • 55349135866 scopus 로고    scopus 로고
    • Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis
    • Schiff E, Simsek H, Lee WM et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am. J. Gastroenterol. 103 (11), 2776-2783 (2008).
    • (2008) Am. J. Gastroenterol , vol.103 , Issue.11 , pp. 2776-2783
    • Schiff, E.1    Simsek, H.2    Lee, W.M.3
  • 44
    • 66149190942 scopus 로고    scopus 로고
    • Side effects of long-term oral antiviral therapy for hepatitis B
    • Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 49 (5, Suppl.), S185-S195 (2009).
    • (2009) Hepatology , vol.49 , Issue.5 and SUPPL.
    • Fontana, R.J.1
  • 45
    • 24344478565 scopus 로고    scopus 로고
    • Molecular virology and the development of resistant mutants: Implications for therapy
    • Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy. Semin. Liver Dis. 25 (Suppl. 1), 9-19 (2005).
    • (2005) Semin. Liver Dis , vol.25 , Issue.SUPPL. 1 , pp. 9-19
    • Locarnini, S.1
  • 46
    • 10744225554 scopus 로고    scopus 로고
    • Long-term safety of lamivudine treatment in patients with chronic hepatitis B
    • Lok AS, Lai CL, Leung N et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125 (6), 1714-1722 (2003).
    • (2003) Gastroenterology , vol.125 , Issue.6 , pp. 1714-1722
    • Lok, A.S.1    Lai, C.L.2    Leung, N.3
  • 47
    • 33845671388 scopus 로고    scopus 로고
    • Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years
    • Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131 (6), 1743-1751 (2006).
    • (2006) Gastroenterology , vol.131 , Issue.6 , pp. 1743-1751
    • Hadziyannis, S.J.1    Tassopoulos, N.C.2    Heathcote, E.J.3
  • 48
    • 4344627233 scopus 로고    scopus 로고
    • Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine
    • Tenney DJ, Levine SM, Rose RE et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob. Agents Chemother. 48 (9), 3498-3507 (2004).
    • (2004) Antimicrob. Agents Chemother , vol.48 , Issue.9 , pp. 3498-3507
    • Tenney, D.J.1    Levine, S.M.2    Rose, R.E.3
  • 49
    • 43049174567 scopus 로고    scopus 로고
    • Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response
    • Baldick CJ, Eggers BJ, Fang J et al. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. J. Hepatol. 48 (6), 895-902 (2008).
    • (2008) J. Hepatol , vol.48 , Issue.6 , pp. 895-902
    • Baldick, C.J.1    Eggers, B.J.2    Fang, J.3
  • 50
    • 33644882231 scopus 로고    scopus 로고
    • Treatment with Peg-interferon α-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype
    • Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL. Treatment with Peg-interferon α-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am. J. Gastroenterol. 101 (2), 297-303 (2006).
    • (2006) Am. J. Gastroenterol , vol.101 , Issue.2 , pp. 297-303
    • Flink, H.J.1    van Zonneveld, M.2    Hansen, B.E.3    de Man, R.A.4    Schalm, S.W.5    Janssen, H.L.6
  • 51
    • 21244447705 scopus 로고    scopus 로고
    • Peginterferon α-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
    • Lau GK, Piratvisuth T, Luo KX et al. Peginterferon α-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 352 (26), 2682-2695 (2005).
    • (2005) N. Engl. J. Med , vol.352 , Issue.26 , pp. 2682-2695
    • Lau, G.K.1    Piratvisuth, T.2    Luo, K.X.3
  • 52
    • 19944428132 scopus 로고    scopus 로고
    • Pegylated interferon a-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial
    • Janssen HL, van Zonneveld M, Senturk H et al. Pegylated interferon a-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365 (9454), 123-129 (2005).
    • (2005) Lancet , vol.365 , Issue.9454 , pp. 123-129
    • Janssen, H.L.1    van Zonneveld, M.2    Senturk, H.3
  • 53
    • 33644539558 scopus 로고    scopus 로고
    • Therapy of hepatitis B - viral suppression or eradication?
    • Perrillo R P. Therapy of hepatitis B - viral suppression or eradication? Hepatology 43 (2, Suppl. 1), S182-S193 (2006).
    • (2006) Hepatology , vol.43 , Issue.2 and SUPPL. 1
    • Perrillo, R.P.1
  • 54
    • 39549114267 scopus 로고    scopus 로고
    • HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon a-2a for HBeAg-positive chronic hepatitis B
    • Fried MW, Piratvisuth T, Lau GK et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon a-2a for HBeAg-positive chronic hepatitis B. Hepatology 47 (2), 428-434 (2008).
    • (2008) Hepatology , vol.47 , Issue.2 , pp. 428-434
    • Fried, M.W.1    Piratvisuth, T.2    Lau, G.K.3
  • 55
    • 34247538953 scopus 로고    scopus 로고
    • Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
    • Bonino F, Marcellin P, Lau GK et al. Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 56 (5), 699-705 (2007).
    • (2007) Gut , vol.56 , Issue.5 , pp. 699-705
    • Bonino, F.1    Marcellin, P.2    Lau, G.K.3
  • 56
    • 5044229895 scopus 로고    scopus 로고
    • High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance
    • Andreone P, Gramenzi A, Cursaro C et al. High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance. J. Viral Hepat. 11 (5), 439-442 (2004).
    • (2004) J. Viral Hepat , vol.11 , Issue.5 , pp. 439-442
    • Andreone, P.1    Gramenzi, A.2    Cursaro, C.3
  • 57
    • 34547148385 scopus 로고    scopus 로고
    • Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B
    • Keeffe EB, Zeuzem S, Koff RS et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin. Gastroenterol. Hepatol. 5 (8), 890-897 (2007).
    • (2007) Clin. Gastroenterol. Hepatol , vol.5 , Issue.8 , pp. 890-897
    • Keeffe, E.B.1    Zeuzem, S.2    Koff, R.S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.